CG Oncology, Inc. Common stock (CGON) 10-Year Financial Performance & Capital Metrics

CGON • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.Show more

Revenue $1M +458.3%
EBITDA -$115M -106.8%
Net Income -$88M -81.1%
EPS (Diluted) -1.41 -38.2%
Gross Margin 100%
EBITDA Margin -10064.44% +63.0%
Operating Margin -10067.25% +63.0%
Net Margin -7729.5% +67.6%
ROE -19.18% +38.9%
ROIC -26.3% +27.1%
Debt/Equity 0.00 -94.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 93 (top 7%)
✓Share count reduced 6.2% through buybacks

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-52.09%

TTM217.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-109.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM-81.42%

ROCE

10Y Avg-30.48%

5Y Avg-30.48%

3Y Avg-32.67%

Latest-24.97%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.36M	191K	204K	1.14M
Revenue Growth %	-	-0.98%	0.07%	4.58%
Cost of Goods Sold+	10K	15K	0	0
COGS % of Revenue	0%	0.08%	-	-
Gross Profit+	10.35M	176K	204K	1.14M
Gross Margin %	1%	0.92%	1%	1%
Gross Profit Growth %	-	-0.98%	0.16%	4.58%
Operating Expenses+	22.95M	35.42M	55.65M	115.81M
OpEx % of Revenue	2.22%	185.46%	272.81%	101.67%
Selling, General & Admin	4.63M	6.39M	9.9M	33.7M
SG&A % of Revenue	0.45%	33.47%	48.53%	29.59%
Research & Development	18.32M	29.03M	45.75M	82.1M
R&D % of Revenue	1.77%	151.98%	224.27%	72.08%
Other Operating Expenses	0	0	0	0
Operating Income+	-12.61M	-35.25M	-55.45M	-114.67M
Operating Margin %	-1.22%	-184.53%	-271.81%	-100.67%
Operating Income Growth %	-	-1.8%	-0.57%	-1.07%
EBITDA+	-12.6M	-35.23M	-55.43M	-114.63M
EBITDA Margin %	-1.22%	-184.46%	-271.73%	-100.64%
EBITDA Growth %	-	-1.8%	-0.57%	-1.07%
D&A (Non-Cash Add-back)	10K	15K	17K	32K
EBIT	-12.39M	-35.25M	-55.45M	-114.67M
Net Interest Income+	-451K	-1K	6.9M	26.62M
Interest Income	0	0	6.9M	26.62M
Interest Expense	451K	1K	0	0
Other Income/Expense	-233K	-197K	6.84M	26.63M
Pretax Income+	-12.84M	-35.44M	-48.61M	-88.04M
Pretax Margin %	-1.24%	-185.57%	-238.27%	-77.29%
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-12.84M	-35.44M	-48.61M	-88.04M
Net Margin %	-1.24%	-185.57%	-238.27%	-77.29%
Net Income Growth %	-	-1.76%	-0.37%	-0.81%
Net Income (Continuing)	-12.84M	-35.44M	-48.61M	-88.04M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.28	-0.66	-1.02	-1.41
EPS Growth %	-	-1.36%	-0.55%	-0.38%
EPS (Basic)	-0.28	-0.66	-1.02	-1.41
Diluted Shares Outstanding	66.64M	66.64M	66.64M	62.5M
Basic Shares Outstanding	66.64M	66.64M	66.64M	62.5M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	58.41M	147.21M	194.12M	754.21M
Cash & Short-Term Investments	53.61M	143.48M	187.67M	742M
Cash Only	53.61M	88.14M	8.27M	257.07M
Short-Term Investments	0	55.34M	179.41M	484.93M
Accounts Receivable	2K	303K	92K	781K
Days Sales Outstanding	0.07	579.03	164.61	250.28
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	4.8M	3.42M	6.36M	11.43M
Total Non-Current Assets+	285K	539K	5.18M	587K
Property, Plant & Equipment	200K	506K	491K	493K
Fixed Asset Turnover	51.79x	0.38x	0.42x	2.31x
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	85K	33K	4.69M	94K
Total Assets+	58.69M	147.75M	199.3M	754.8M
Asset Turnover	0.18x	0.00x	0.00x	0.00x
Asset Growth %	-	1.52%	0.35%	2.79%
Total Current Liabilities+	5.97M	15.43M	14.25M	21.37M
Accounts Payable	1M	985K	3.24M	6.52M
Days Payables Outstanding	36.61K	23.97K	-	-
Short-Term Debt	2.94M	8.97M	569K	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	1.13M	173K	547K	436K
Current Ratio	9.78x	9.54x	13.62x	35.30x
Quick Ratio	9.78x	9.54x	13.62x	35.30x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	12.46M	7.14M	257K	52K
Long-Term Debt	12.06M	6.53M	0	0
Capital Lease Obligations	50K	257K	244K	52K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	351K	352K	13K	0
Total Liabilities	18.44M	22.57M	14.51M	21.42M
Total Debt+	15.13M	15.94M	1.03M	238K
Net Debt	-38.48M	-72.2M	-7.24M	-256.83M
Debt / Equity	0.38x	0.13x	0.01x	0.00x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-27.95x	-35246.00x	-	-
Total Equity+	40.25M	125.18M	184.79M	733.38M
Equity Growth %	-	2.11%	0.48%	2.97%
Book Value per Share	0.60	1.88	2.77	11.73
Total Shareholders' Equity	40.25M	125.18M	184.79M	733.38M
Common Stock	0	0	0	8K
Retained Earnings	-45.89M	-81.33M	-129.94M	-217.98M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.65M	-29.8M	-45.68M	-78.71M
Operating CF Margin %	-1.32%	-156.04%	-223.92%	-69.11%
Operating CF Growth %	-	-1.18%	-0.53%	-0.72%
Net Income	-12.84M	-35.44M	-48.61M	-88.04M
Depreciation & Amortization	10K	15K	17K	32K
Stock-Based Compensation	1.11M	676K	1.53M	11.4M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	30K	509K	-2.06M	-5.01M
Working Capital Changes	-1.97M	4.44M	3.44M	2.91M
Change in Receivables	0	0	0	-689K
Change in Inventory	0	0	0	0
Change in Payables	578K	-18K	2.01M	3.27M
Cash from Investing+	-97K	-55.35M	-121.19M	-300.76M
Capital Expenditures	-97K	-14K	0	-234K
CapEx % of Revenue	0.01%	0.07%	-	0.21%
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	15.45M	119.69M	87M	628.28M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	-1.34M	-825K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-13.75M	-29.82M	-45.68M	-78.95M
FCF Margin %	-1.33%	-156.12%	-223.92%	-69.31%
FCF Growth %	-	-1.17%	-0.53%	-0.73%
FCF per Share	-0.21	-0.45	-0.69	-1.26
FCF Conversion (FCF/Net Income)	1.06x	0.84x	0.94x	0.89x
Interest Paid	0	0	376K	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-31.9%	-42.85%	-31.36%	-19.18%
Return on Invested Capital (ROIC)	-	-96.56%	-36.08%	-26.3%
Gross Margin	99.9%	92.15%	100%	100%
Net Margin	-123.95%	-18556.54%	-23826.96%	-7729.5%
Debt / Equity	0.38x	0.13x	0.01x	0.00x
Interest Coverage	-27.95x	-35246.00x	-	-
FCF Conversion	1.06x	0.84x	0.94x	0.89x
Revenue Growth	-	-98.16%	6.81%	458.33%

Frequently Asked Questions

Growth & Financials

CG Oncology, Inc. Common stock (CGON) reported $2.2M in revenue for fiscal year 2024. This represents a 79% decrease from $10.4M in 2021.

CG Oncology, Inc. Common stock (CGON) grew revenue by 458.3% over the past year. This is strong growth.

CG Oncology, Inc. Common stock (CGON) reported a net loss of $151.5M for fiscal year 2024.

Dividend & Returns

CG Oncology, Inc. Common stock (CGON) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

CG Oncology, Inc. Common stock (CGON) had negative free cash flow of $117.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener